Current concepts of management in radiotherapy for head and neck squamous-cell cancer.

Détails

ID Serval
serval:BIB_2B516D15FE9F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Current concepts of management in radiotherapy for head and neck squamous-cell cancer.
Périodique
Oral Oncology
Auteur(s)
Mazeron R., Tao Y., Lusinchi A., Bourhis J.
ISSN
1879-0593 (Electronic)
ISSN-L
1368-8375
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
45
Numéro
4-5
Pages
402-408
Langue
anglais
Notes
Publication types: Journal Article ; Review Publication Status: ppublish
Résumé
Radiotherapy plays a key role in the management of early stage and locally advanced head and neck squamous-cell carcinomas (HNSCC) either alone or, more frequently combined with surgery and/or chemotherapy. Several approaches have been developed to improve its efficacy while maintaining acceptable toxicities, such as altered fractionated radiotherapy or concomitant chemoradiotherapy which have both improved the anti-tumor efficacy of radiotherapy. Of particular interest is concomitant chemoradiotherapy (CT-RT) which is the most commonly used approach in locally advanced disease. Taxanes and platinum-based induction chemotherapy could constitute an option in the treatment of locally advanced HNSCC and it's contribution before concomitant RT-CT is currently under investigation. More recently, epidermal growth factor receptor (EGFr) molecular targeting with cetuximab combined with radiotherapy has been successfully tested in a large randomized trial and this combination constitutes a new option, especially for patients with medical co-morbidities. Finally management of treatment related acute or late toxicity remains an important issue and in the last decade major achievements have been obtained in this field especially using intensity modulated radiotherapy (IMRT).
Mots-clé
Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents/therapeutic use, Carcinoma, Squamous Cell/drug therapy, Carcinoma, Squamous Cell/radiotherapy, Cell Hypoxia, Chemotherapy, Adjuvant/methods, Combined Modality Therapy/methods, Head and Neck Neoplasms/drug therapy, Head and Neck Neoplasms/radiotherapy, Humans, Platinum Compounds/therapeutic use, Radiotherapy, Adjuvant/methods, Taxoids/therapeutic use, Treatment Outcome
Pubmed
Création de la notice
01/12/2014 17:20
Dernière modification de la notice
20/08/2019 13:10
Données d'usage